Clinical trials: Carrier State
Typhoid Fever
Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adult (18-40 Years Old)
This trial is aimed to evaluate the safety and immunogenicity profiles of a new Vi-CRM197 conjugate vaccine against S. Typhi in healthy human adults in comparison with the currently licensed Vi polysaccharide vaccine.
- Trial name
- NCT01123941
- Testing
- Typherix, NVGH Vi-CRM197
- Where
- Belgium
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Novartis
Infectious Disease, Bacterial Infections
Safety & Efficacy of an Antibacterial Protein Molecule Applied Topically to the Nostrils of Volunteers and Patients
The purpose of this study is to determine whether the antibacterial protein P128 is (i) safe and well tolerated in healthy volunteers and in chronic kidney diseases patients on dialysis, (ii) is it effective in reducing the nasal…
- Trial name
- NCT01746654
- Testing
- P128-0.1 mg, P128-0.3 mg, P128-1.0 mg
- Where
- Singapore
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- GangaGen, Inc.
Meningioma, Boron Neutron Capture Therapy
A Study of the Boron Neutron Capture Therapy (BNCT) Using B10 L-BPA in Recurrent Meningioma
This Phase I/II study, titled 'A Study to Evaluate the Safety and Efficacy of Boron Neutron Capture Therapy (BNCT) Using B10 L-BPA as a Boron Carrier in Recurrent Meningioma', aims to assess the efficacy of B10 L-BPA with BNCT in…
- Trial name
- NCT06668987
- Testing
- B10 L-BPA Injection
- Where
- Taiwan
- Volunteers
- 10 people
- Sponsor
- Heron Neutron Medical Corp.
Coronary Artery Disease
Safety and Efficacy Study of the Svelte Drug-Eluting Coronary Stent Delivery System
A prospective, randomized, active-control, multi-center clinical trial comparing the safety and efficacy of the Svelte Drug-Eluting Coronary Stent Integrated Delivery System (IDS) to that of the commercially available Resolute…
- Trial name
- DIRECT II (NCT01788150)
- Testing
- Coronary Stenting
- Where
- 18 sites in Belgium, Czechia and 5 more
- Volunteers
- 159 people
- Sponsor
- Svelte Medical Systems, Inc.
Coronary Artery Disease
The Direct III Post Market Study
The primary objective of this multicenter, single-arm, observational study is to evaluate the feasibility of a systematic direct stenting strategy with the Svelte SLENDER IDS Sirolimus-Eluting Coronary Stent-on-a-Wire Integrated…
- Trial name
- Direct III (NCT02693158)
- Where
- 8 sites in Netherlands
- Volunteers
- 440 people
- Sponsor
- Svelte Medical Systems, Inc.
Ornithine Transcarbamylase Deficiency
Study to Characterize Rate of Ureagenesis in Patients With Ornithine Transcarbamylase (OTC) Deficiency
The objectives of the study are to characterize urea production rates in patients with OTC, characterize the association of rate of ureagenesis and disease severity in OTC patients, characterize the association of rate of…
- Trial name
- NCT04717453
- Testing
- No Intervention
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Ultragenyx Pharmaceutical Inc
Diabetes
Comparison of Safety and Efficacy of QS-M Needle- Free Injector and Insulin Pen in Controlling T2DM Patient's Glucose
In this study, QS-M needle-free injector and needle-insulin pen were used as a drug carrier to control blood glucose in type 2 diabetic patients（T2DM）.The efficacy and safety of QS-M needle-free injector and needle-insulin pen…
- Trial name
- NCT03243903
- Testing
- QS-M insulin-free injector, conventional insulin pen
- Where
- China
- Volunteers
- 427 people
- Sponsor
- Beijing QS Medical Technology Co., Ltd.
Spinal Muscular Atrophy (SMA), Carrier Screening
Multi-disease Carrier Screening Test Validation
The purpose of this study is to collect blood samples to enable validation of genetic testing for diseases within a multi-disease carrier screening panel.
- Conditions
- Spinal Muscular Atrophy (SMA), Carrier Screening, Genetic Testing
- Trial name
- NCT01663584
- Testing
- Blood draw
- Where
- United States
- Sponsor
- Natera, Inc.
Metastatic Breast Cancer
Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer
The primary objective of the study is to assess the progression-free survival (PFS) of oral veliparib in combination with TMZ or in combination with carboplatin and paclitaxel compared to placebo plus carboplatin and paclitaxel…
- Trial name
- NCT01506609
- Testing
- Veliparib, Carboplatin, Temozolomide
- Where
- 120 sites in United States, Argentina and 18 more
- Volunteers
- 294 people
- Sponsor
- AbbVie
Traumatic Brain Injury
Study of Oxycyte in Severe Closed Head Injury
Brain damage as a result of decreased oxygen to the brain is found in 80% of patients that die with severe head injuries. Laboratory studies in animals and clinical trials have shown that increasing oxygen in the brain results in…
- Trial name
- NCT00174980
- Testing
- Oxycyte
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Tenax Therapeutics, Inc.
Psoriasis Vulgaris
The Efficacy Of A Dead Sea Mineral Enriched Body Cream vs Its Carrier as an Adjuvant Treatment For Psoriatic Patients
This is a two-center study aimed to assess the efficacy of Dead Sea Minerals in alleviating symptoms of Psoriasis Vulgaris, in 50 patients undergoing phototherapy.
- Trial name
- NCT01651559
- Where
- 2 sites in Israel
- Volunteers
- 50 people
- Sponsor
- Ahava Dead Sea Laboratories
Alzheimer's Disease
Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier)
This is a multicenter, double-blind, placebo controlled, randomized, outpatient multiple dose study in male and female patients ages 50 to less than 89 years with mild to moderate AD.
- Trial name
- NCT00574132
- Testing
- Bapineuzumab 0.5 mg/kg, Bapineuzumab 1.0 m/kg
- Where
- 251 sites in United States, Austria and 2 more
- Volunteers
- 1,331 people
- Sponsor
- JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Diagnoses Disease
Evaluation of HemoTypeSC as a Novel Rapid Test for Point-of-Care Screening for Sickle-Cell Disease, Hemoglobin C Disease, and Carrier Status in Low-Resource Settings
Sickle cell disease is a life-threatening genetic disorder that can be effectively treated following early diagnosis via newborn screening.
- Trial name
- NCT03619798
- Testing
- HemoTypeSC
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Silver Lake Research Corporation
Alzheimer's Disease
Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier)
This is a multicenter, double-blind, placebo controlled, randomized, outpatient, multiple dose study in male and female patients ages 50 to less than 89 years with mild to moderate AD.
- Trial name
- NCT00575055
- Testing
- Bapineuzumab 0.5 mg/kg, Bapineuzumab 1.0 m/kg
- Where
- 186 sites in United States
- Volunteers
- 1,121 people
- Sponsor
- JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Hereditary Amyloidosis, Transthyretin-Related, Asymptomatic Carrier State
Observational Study of Neurofilament Light Chain (NfL) as a Biomarker in Asymptomatic Carriers of the Transthyretin (TTR) Variants and Patients With Hereditary Transthyretin-mediated (hATTR) Amyloidosis With Polyneuropathy
This is a single-center observational study evaluating the potential value of NfL as a biomarker for diagnosis, detection of disease onset, monitoring of disease progression, and treatment response in asymptomatic carriers of TTR…
- Trial name
- NCT06360289
- Testing
- Standard of Care
- Where
- France
- Volunteers
- 346 people, healthy volunteers welcome
- Sponsor
- Alnylam Pharmaceuticals
Strept Throat
Rapid Strep Test Results
This is a prospective study seeks to determine how often a rapid antigens test for group A streptococcus is positive in healthy adults
- Trial name
- NCT04256694
- Testing
- Rapid Antigen Test for Group A Streptococcus
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Kendall Healthcare Group, Ltd.
Alzheimer's Disease
A Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-Dominant Alzheimer's Disease (AD), Including a Placebo-Treated Non-Carrier Cohort
This study consists of 2 periods: [1] Study Period A - evaluating the efficacy and safety of Crenezumab versus Placebo in participants who carry the PSEN1 E280A autosomal-dominant mutation and do not meet the criteria for mild…
- Trial name
- NCT01998841
- Testing
- Crenezumab
- Where
- 4 sites in Colombia
- Volunteers
- 252 people
- Sponsor
- Genentech, Inc.
Respiratory Syncytial Viral Infections
Phase I Study for SynGEM, an Intranasal Respiratory Syncytial Virus (RSV) Prefusion F Subunit Candidate Vaccine
The study is a double-blind (within dose level), placebo-controlled Phase I study to assess the safety, reactogenicity and tolerability of two intranasal dose levels of SynGEM®: a low dose level (140 μg F-protein/2mg BLPs) and a…
- Trial name
- SynGEM (NCT02958540)
- Testing
- SynGEM
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Mucosis BV
Type2 Diabetes, NASH - Nonalcoholic Steatohepatitis
A Study of MSDC-0602K to Assess Glycemic Control and Cardiovascular Outcomes in Patients With Pre-T2D or T2D and NAFLD/NASH
This is a randomized, double-blind study of MSDC-0602K or placebo in subjects with pre-T2D or T2D and evidence of NAFLD/NASH.
- Conditions
- Type2 Diabetes, NASH - Nonalcoholic Steatohepatitis, Nonalcoholic Steatohepatitis, Non-Alcoholic Fatty Liver Disease
- Trial name
- NCT03970031
- Testing
- MSDC-0602K
- Volunteers
- 1,800 people
- Sponsor
- Cirius Therapeutics, Inc.
Hypohidrotic Ectodermal Dysplasia, X-Linked Hypohidrotic Ectodermal Dysplasia
X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED) Carrier Outlook Toward Reproduction Survey
In this survey of X-Lined Hypohidrotic Ectodermal Dysplasia (XLHED) carrier females, Edimer proposes to review responses to an XLHED Carrier Outlook toward Reproduction Survey in order to understand attitudes toward reproduction…
- Trial name
- X-CORS (NCT01398813)
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Edimer Pharmaceuticals